Medical Device Royalty Kickbacks: Paying for an Invention, Expecting Implant Sales

Medical device royalty kickbacks use royalties or intellectual property payments to buy a surgeon’s use or recommendation of a manufacturer’s products. The agreement may describe a patent, a design contribution or a future product. The sales department may measure something else entirely: how much hardware that surgeon implants. If you work with those agreements, payments or development files, the difference between what the contract describes and what management expects is what we help you turn into a case.

Device companies rely on surgeons to help design implants, evaluate instruments and teach techniques. That gives the relationship both technical value and commercial reach. A surgeon can contribute to a product and influence who buys it. The important evidence connects the payment to what the manufacturer expected the surgeon to do with that influence.

How Does Reimbursement Work for Medical Devices?

Medicare usually pays for an implanted device within the hospital’s procedure or inpatient-stay payment. The hospital buys the implant, while the surgeon often chooses the brand and device type. That puts the royalty recipient and the institution submitting the claim on different sides of the purchase.

The Department of Health and Human Services’ Office of Inspector General explains this purchasing structure in its alert on physician-owned entities, calling implants physician preference items. The surgeon’s preference carries commercial weight because it can determine which manufacturer’s product the hospital purchases.

Consignment makes the connection especially concrete. When the manufacturer retains ownership until use, implantation turns hospital inventory into a sale. The surgeon’s operating-room decision then determines which manufacturer gets paid.

The bill tells only part of that story. A hospital claim may identify a spinal fusion without identifying the implanted model by its unique device identifier. Product-use records and hospital purchasing records supply the connection between the surgeon, the manufacturer’s sale and the procedure billed to Medicare or Medicaid. That is the path a royalty kickback case has to explain.

Why Is Kickback Illegal?

A 2020 paper in the Journal of Forensic and Investigative Accounting explains why the purpose of a payment matters even when the arrangement has other purposes. Describing the courts’ one-purpose test, it says:

What Are Some Examples of Kickbacks in Healthcare?

Medical device royalty and IP kickback cases show different ways to connect a payment to product use. Life Spine’s civil admissions describe management measuring the return on surgeon payments. The allegations involving Arthrex, Innovasis and Spine 360 reach recommendations, unused intellectual property and payments routed through a surgeon-controlled entity.

Life Spine Measured the Return on Surgeon Payments

Life Spine admitted that it tracked surgeon payments against product use in its civil settlement announced in November 2019. Its agreements paid consulting fees, royalties and intellectual property acquisition payments. Approximately 21 of its top 30 users received those payments, and approximately half of its domestic spinal-product sales came from surgeries performed by paid surgeons.

Management reports put the payments beside each surgeon’s use. One report calculated return on investment by dividing sales revenue associated with the surgeon’s use by the consulting fees and royalties paid to that surgeon. When use fell, senior sales managers contacted surgeons or their distributors to urge more use. The company was measuring implant sales against what it paid the person choosing the implants.

The case also reached a compression-plate development project. The company spent money trying to bring it to market but encountered setbacks. In his civil settlement, the business-development executive admitted discussing continued project funding alongside the surgeon’s declining use of Life Spine products and asking the surgeon to use them more frequently. Funding a future product had become part of a conversation about selling existing ones.

Arthrex and the Value of a Surgeon’s Recommendation

Arthrex’s November 2021 settlement addressed royalties purportedly paid for a surgeon’s contributions to SutureBridge and SpeedBridge. The government alleged that the payments were intended to induce the surgeon’s use and recommendation of Arthrex products, causing false Medicare claims. Arthrex agreed to pay $16 million. The whistleblower’s complaint put one surgeon’s royalty payments at about $6 million.

Those were marketed products. The government’s theory focused on what the royalties were intended to buy. The complaint separately alleged that surgeons on large royalty agreements were expected to use Arthrex products, speak about them and train others on them, while refraining from doing the same for competitors.

That allegation reaches beyond the recipient’s own operating schedule. A surgeon who teaches other physicians can influence purchases made for other surgeons’ patients.

Innovasis and the Product That Never Developed

Innovasis allegedly paid physicians above fair market value to acquire or license intellectual property without obtaining a valuation before the purchase, then never used it for meaningful product development. Its May 2024 resolution required the company and two executives to pay $12 million collectively over allegations of payments intended to induce use of its spinal devices in procedures for Medicare beneficiaries.

For one development arrangement, the whistleblower alleged Innovasis paid surgeons over $1,044,000 per year without taking a meaningful step to develop the system.

According to the whistleblower’s complaint, a sales executive said a neurosurgeon used Innovasis products because of royalty payments and would probably stop when the agreement expired, even though the company did not use, develop or sell the product covered by the agreement.

In that account, royalties paid for a product the company never made while the surgeon kept buying the products it did. The complaint also alleged that product developers received inquiries from surgeons trying to advance inventions but had to tell them the company had refused to fund the work. That places the development team beside the sales team as a source of evidence. One knows what happened to the promised product. The other knows what sales the arrangement was expected to produce.

Spine 360 and the Surgeon-Controlled Payee

Spine 360’s alleged IP arrangement sent payments to an entity controlled by a spinal surgeon. The United States contended that the intellectual property agreements were shams intended to compensate the surgeon for using the company’s products in surgery.

Omni Surgical, doing business as Spine 360, and the surgeon agreed to pay $2.6 million jointly in August 2014. The government alleged the payment trail went through a business controlled by the person selecting the devices. For an insider looking at an IP vendor account, ownership of the payee can explain the connection that the vendor’s name leaves out.

What Kind of Proof Is Needed to Be a Whistleblower?

Useful proof in a royalty kickback case shows what the manufacturer paid for and what it expected in return. Your knowledge may come from sales, engineering or finance. We work with you to connect that knowledge to the surgeon’s decisions and the government-paid procedures.

The Invention and the Work Behind It

In the Life Spine case, the whistleblower alleged that patent-application purchase agreements concerned devices already on the market and transferred no intellectual property. That allegation challenges what the company bought in the first place. We examine the promised contribution alongside engineering work, funding decisions and communications with the surgeon about the project’s progress.

The Valuation and the Surgeon Selected

Innovasis allegedly bought or licensed intellectual property without first obtaining a valuation. Life Spine’s management reports measured payments against the business each surgeon generated. Those cases put the price and the choice of recipient together: we examine what the company valued, the technical contribution or the sales influence.

The Sales That Generate a Royalty

A royalty on the surgeon’s own cases connects implant selection to personal income. An up-front IP acquisition fee pays for an asset before a product reaches the market. Life Spine’s funding discussions show why we look beyond the payment formula to what management expected the surgeon to buy. We compare the agreement with the sales expectations and the work the company actually funded.

Open Payments and the Company’s Own Description

Open Payments includes royalty or license as a distinct payment category, recording the manufacturer’s characterization of the transfer. We compare that description with the agreement, the work performed and the surgeon’s product use. The internal accounts carry parts of the commercial relationship that public reporting leaves out.

The Implant and the Institutional Claim

The Innovasis whistleblower was a former regional sales director. A sales or engineering insider may understand the payment arrangement long before anyone looking at the hospital bill could see it. You can contact us about the manufacturer’s side of the deal without having the hospital’s billing records. We work with you and medical device whistleblower lawyers to connect the payment arrangement to the device purchases and resulting claims.

How Much Can a Medical Device Whistleblower Case Pay?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. For royalty and IP cases, we focus on the connection between the company’s payments, the surgeon’s decisions and the claims those decisions generated.

When You Know What the Payment Bought

If you know why a surgeon received an IP payment, or why a development agreement kept producing sales but no product, speak with our whistleblower experts about that arrangement. We work beside you to build the case around the payment, the decisions inside the manufacturer and the resulting claims. We bring in medical device kickback whistleblower lawyers who understand royalty agreements and institutional billing, and stay with you through the case.